Department of Geriatric Medicine, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
Drugs Aging. 2010 Jan 1;27(1):39-50. doi: 10.2165/11319540-000000000-00000.
The main aims of the study were to explore whether oral anticoagulation (OAC) for atrial fibrillation (AF) in geriatric outpatients is prescribed in accordance with international (American College of Cardiology/American Heart Association/European Society of Cardiology [ACC/AHA/ESC]) and Dutch national guidelines for the general practitioner (GP) and to identify whether age and selected co-morbid conditions are associated with undertreatment. As a secondary objective, we wanted to establish how many patients discontinue OAC because of major bleeding.
In 2004, at the first visit of all patients to the geriatric day clinic of the Slotervaart Hospital in Amsterdam, the Netherlands, demographic data, Mini-Mental State Examination score, medical history, Charlson Comorbidity Index score, and data on medication use and changes were documented. The presence of AF was established by assessment of medical history information obtained by the GP, the history taken from patients and their caregivers, and the results of clinical evaluation, including ECG findings. Associations between the use of OAC, demographic data and co-morbid conditions registered in the Dutch NHG (Nederlands Huisartsen Genootschap [Dutch College of General Practitioners]) standard for GPs as risk factors for stroke or contraindications to the use of OAC were analysed. The reasons for discontinuing OAC were assessed after 4 years by requesting the information from the anticoagulation services or the GP.
At the time of the initial visit, 17.5% of the 807 outpatients had chronic AF (n = 135) or were known to have paroxysmal AF (n = 6). The mean age of the 141 patients in this cohort was 84.3 years (SD 6.2 years). Co-morbid conditions increasing the risk of stroke were present in 129 patients (91.5%). Contraindications to the use of OAC were observed in 118 patients (83.7%). Of the 116 patients with AF in their history before their visit, 57.8% were being treated with OAC at the time of their visit. After comprehensive geriatric assessment, 73 (51.8%) of the 141 patients with chronic or paroxysmal AF were continued on OAC. Of the 141 patients with chronic or paroxysmal AF, 110 (78.0%) had both extra stroke risk factors and contraindications to the use of OAC. Only increasing age was significantly and independently associated with not being prescribed anticoagulants (p < 0.001). At the 4-year follow-up, OAC had been discontinued in 5.5% of patients because of major bleeding; three patients (4.1%) taking OAC had died as a result of major bleeding, and one other patient had discontinued treatment because of a major, non-lethal bleeding episode.
Applying the NHG standard for appropriate prescription, and disregarding age as a risk factor or contraindication, in this population, 14 of 141 patients (9.9%) were inappropriately prescribed OAC, salicylates or no prophylaxis. Since only patient age was associated with not prescribing OAC in this study, higher age still seems to be considered the most important contraindication to anticoagulation therapy. Implementation of better models for stratifying bleeding risk in the frail elderly is needed. After 4 years, the cumulative rate of bleeding causing discontinuation of anticoagulation therapy in this usual-care study of frail older patients was not alarmingly higher than in other usual-care studies.
本研究的主要目的是探讨老年门诊房颤患者(AF)是否根据国际(美国心脏病学会/美国心脏协会/欧洲心脏病学会 [ACC/AHA/ESC])和荷兰全科医生(GP)国家指南规范使用口服抗凝剂(OAC),并确定年龄和选定的合并症是否与治疗不足相关。作为次要目标,我们希望确定有多少患者因大出血而停止 OAC 治疗。
2004 年,在荷兰阿姆斯特丹 Slotervaart 医院老年日间诊所所有患者的首次就诊时,记录人口统计学数据、简易精神状态检查评分、病史、Charlson 合并症指数评分以及药物使用和变化的数据。通过评估 GP 获取的病史信息、患者及其护理人员提供的病史以及包括心电图结果在内的临床评估结果来确定 AF 的存在。分析 OAC 使用与荷兰 NHG(荷兰家庭医生协会)GP 标准中登记的人口统计学数据和合并症作为中风风险因素或 OAC 使用禁忌之间的关联。通过向抗凝服务机构或 GP 索要信息,在 4 年后评估停止 OAC 的原因。
在初始就诊时,17.5%的 807 名门诊患者患有慢性 AF(n=135)或已知患有阵发性 AF(n=6)。该队列中的 141 名患者的平均年龄为 84.3 岁(SD 6.2 岁)。有 129 名患者存在增加中风风险的合并症(91.5%)。有 118 名患者(83.7%)存在 OAC 使用禁忌证。在就诊前有 AF 病史的 116 名患者中,57.8%在就诊时正在接受 OAC 治疗。经过全面的老年评估后,在 141 名患有慢性或阵发性 AF 的患者中,有 73 名(51.8%)继续接受 OAC 治疗。在 141 名患有慢性或阵发性 AF 的患者中,有 110 名(78.0%)既有额外的中风风险因素,又有 OAC 使用禁忌证。只有年龄增长与未开具抗凝药物显著相关(p<0.001)。在 4 年的随访中,有 5.5%的患者因大出血而停止使用 OAC;有 3 名(4.1%)正在服用 OAC 的患者因大出血而死亡,另有 1 名患者因非致命性大出血事件停止治疗。
在该人群中,应用 NHG 标准规范开具处方,且不将年龄作为风险因素或禁忌证,141 名患者中有 14 名(9.9%)处方 OAC、水杨酸盐或无预防措施不当。由于在本研究中仅患者年龄与未开具 OAC 相关,因此年龄较高似乎仍然被认为是抗凝治疗的最重要禁忌证。需要实施更好的模型来分层脆弱老年人的出血风险。在这项对体弱老年人进行常规护理的研究中,4 年后因出血导致抗凝治疗停止的累积率并不比其他常规护理研究中高得惊人。